Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
Phase 2
Completed
NCT04340362
| Condition | Glomerulosclerosis, Focal Segmental |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
|---|
| Status | Completed |
|---|
| Enrollment | 16 participants |
|---|
| Interventions | VX-147 |
|---|
| Start date | Jun 8, 2020 |
|---|
| Completion date | Nov 11, 2021 |
|---|
| Results posted | Jul 10, 2023 |
|---|
Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
Percent Change From Baseline in UPCR
From Baseline up to Week 13 · percent change
| VX-147 | -47.7 percent change |
|---|
| VX-147 | -47.5 percent change |
|---|
| VX-147 | -47.6 percent change |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.